Search
Now showing items 1-4 of 4
Targeting synaptic plasticity in schizophrenia: insights from genomic studies
(2021-08)
Recent genomic findings identify many hundreds of genomic loci that are associated with schizophrenia.
Consistent with data from the pregenomic era, genomic findings implicate synaptic function and plasticity as a tractable ...
Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia
(2021-12)
The cognitive dysfunction experienced by patients with schizophrenia represents a major unmet clinical need. We believe that enhancing synaptic function and plasticity by targeting kalirin may provide a novel means to ...
New drug targets in psychiatry: Neurobiological considerations in the genomics era
(2022-07)
After a period of withdrawal, pharmaceutical companies have begun to reinvest in neuropsychiatric disorders, due to improvements in our understanding of these disorders, stimulated in part by genomic studies. However, ...
CACNA1C (CaV1.2) and other L-type calcium channels in the pathophysiology and treatment of psychiatric disorders: Advances from functional genomics and pharmacoepidemiology
(2022-09)
A role for voltage-gated calcium channels (VGCCs) in psychiatric disorders has long been postulated as part of a broader involvement of intracellular calcium signalling. However, the data were inconclusive and hard to ...